• Applications & Products
    • Applications
    • Products
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Synthetic Serum Replacements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Human Lysozyme
      • Recombinant Human Interleukins
    • Products
      • Cellastim S® – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin® 20 – Recombinant human albumin
      • Optibumin® 25 – Recombinant human albumin
      • Optiferrin® – Recombinant human transferrin
      • Lacromin® – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac® – Recombinant human lysozyme
      • OptiLeukin 2 – Recombinant human IL-2
      • OptiKine™ LIF – Leukemia Inhibitory Factor
      • OptiVERO® – Chemically-defined complete VERO media
  • About InVitria
  • News & Blog
  • Contact Us
  • Knowledge Base
  • Applications
  • Products
  • Contact Us
  • Home
  • Recombinant Human Albumin in Weekend-Free hiPSC Culture – ISSCR Poster

Recombinant Human Albumin in Weekend-Free hiPSC Culture – ISSCR Poster

Published on 30 July 2026

Poster

Davi Lyra-Leite, Mark Stathos, Elliott Renft, Paul W. Burridge

BMEM Bio, InVitria, Department of Pharmacology, Northwestern University

Recombinant Human Albumin Supports Weekend-Free hiPSC Culture and Protein-Free Cardiac Differentiation

Presented at ISSCR by Davi Lyra-Leite (BMEM Bio), Mark Stathos and Elliott Renft (InVitria), and Paul W. Burridge (Northwestern University Feinberg School of Medicine).

The Problem

Weekend-free hiPSC media change schedules save labor, but they have been reported to reduce subsequent differentiation efficiency. This study asked whether adding chemically defined recombinant human albumin (Optibumin) to chemically defined BMEM could close that gap and whether albumin could also replace the ROCK inhibitor step after passaging.

Key Findings

Higher purity than plasma-derived albumin. Native CE analysis showed significantly lower aggregate content in Optibumin rHSA lots than in plasma-derived HSA lots (p < 0.05).

A viable ROCK inhibitor alternative. Optibumin at 2 mg/mL provided cell survival benefit comparable to Chroman 1, and the two were additive when combined (four hiPSC lines, n = 8).

Pluripotency maintained over 10 passages. Growth, morphology, and POU5F1/NANOG expression were preserved across the weekend-free cadence in two hiPSC lines.

Enhanced cardiac differentiation. The combination of 2 mg/mL recombinant human albumin and 2x media volume during the weekend-free step produced the highest troponin T (TNNT2) positivity by flow cytometry, with more beating areas observed.

Why It Matters

For labs running weekend-free hiPSC schedules, chemically defined recombinant albumin offers a way to simplify the protocol by removing a separate ROCK inhibitor addition while recovering downstream cardiomyocyte differentiation efficiency. As an animal-origin-free, chemically defined supplement, Optibumin fits defined workflows without introducing plasma-derived variability.

Download the Poster

Get the full data set, including growth curves, pluripotency marker expression, morphology images, and TNNT2 flow cytometry across all albumin concentrations and media volumes.


The following content is gated. Please, subscribe to open access to it.

  • This field is for validation purposes and should be left unchanged.
  • Required if country is United States or Canada.
Start New Search

Quick Search Links

Application:

Antibody Production

Cell Therapy

Final Formulation

Gene Therapy

T-Cell Immunotherapy

Vaccine Production

Product Category:

Cell Culture Supplements

Albumin

Cell Culture Media

Interleukins

Lactoferrin

LIF

Lysozyme

Single Components

Transferrin

Product:

Exbumin® – Recombinant human albumin excipient

ITS Animal-Free™ – Blood-free cell culture media supplement

ITSE Animal-Free® – Blood-free cell culture media supplement

ITSE+A™ – Blood-free cell culture media supplement

Lacromin® – Recombinant human holo-lactoferrin

OptiLeukin™ 2 – Recombinant human interleukin-2

OptiVERO®

Cellastim® S – Recombinant human albumin

Optibumin® 20 – Recombinant human albumin

Optibumin® 25 – Recombinant human albumin

Optiferrin® – Recombinant human transferrin

OptiKine™ LIF – Leukemia Inhibitory Factor

Lysobac® – Recombinant human lysozyme

Document Type:

Application Notes

Blog

Case Studies

Catalog

Data Sheets

Infographics

Interviews

Journal Articles (DOI Links)

News

Posters

Product Brochures

Product Specifications

Regulatory Documents

SDS

Use Guidelines

Webinar

White Papers

Cell Line:

B Lymphocyte

CHO

ESC

HEK293

Hematopoetic Stem Cells

Hybridoma

iPSC

Mesenchymal Stem Cells

Natural Killer Cells

Neural Stem Cells

T Lymphocyte

VERO

  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2026 InVitria

    • Terms
    • Privacy
    • Sitemap